

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JINTIAN PHARMACEUTICAL GROUP LIMITED **金天醫藥集團股份有限公司**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the English name of the Company from “Jintian Pharmaceutical Group Limited” to “Universal Health International Group Holding Limited” and the Chinese name of the Company from “金天醫藥集團股份有限公司” to “大健康國際集團控股有限公司”.

The proposed Change of Company Name is subject to the fulfillment of the conditions as set out in the section headed “Conditions of the Change of Company Name” in this announcement. A supplemental circular containing, among other things, details of the proposed Change of Company Name and a revised notice of AGM at which the resolutions relating to the proposed Change of Company Name will be put to vote, will be despatched to the Shareholders as soon as practicable.

PROPOSED CHANGE OF COMPANY NAME

The board of directors (the “**Board**”) of Jintian Pharmaceutical Group Limited (the “**Company**”), together with its subsidiaries (the “**Group**”) proposes to change the English name of the Company from “Jintian Pharmaceutical Group Limited” to “Universal Health International Group Holding Limited” and the Chinese name of the Company from “金天醫藥集團股份有限公司” to “大健康國際集團控股有限公司” (the “**Change of Company Name**”).

REASONS FOR THE CHANGE OF COMPANY NAME

1. As an important sector supported by the government of China, the Board believes that the universal health or healthcare and wellness industry will become another blue ocean market with tremendous development potential similar to the internet industry. The Board believes that it now presents the best opportunity for the Group to develop in such business. Leveraging on its outstanding retail and distribution network of pharmaceutical and healthcare products, the Group takes the lead in the development of the universal health sector. Benefiting from its

status as a listed company on the Main Board of The Stock Exchange of Hong Kong Limited and the advantage of Hong Kong as a free-trade port with a history of over a century, the Company is well positioned to introduce international renowned brands of healthcare and wellness products into China and Chinese products into the global market, with the aim of building an international branding and marketing platform in universal health area.

2. The Group has adopted a strategy to diversify its product lines. While continuing to develop its established business of selling and distributing pharmaceutical products, the Group has expanded into imported and domestic healthcare products, health food and other non-pharmaceutical products, as well as traditional nutrition supplements (including cubilose, ginseng, cordyceps etc.), healthcare devices, cosmeceutical and other products.
3. The Group has adopted a cross border development strategy and takes proactive initiatives to develop international trading business. The Group continues to source quality products through entering into distribution agreements with a number of renowned manufacturers globally. Meanwhile, the Group strives to capture opportunities arising from the development of free trade zones across China, to establish its international import business presence. Under the concept of establishing and sharing platform, the Group carries out cross-border cooperations of various scope and depth with a number of domestic and overseas companies engaging in healthcare and wellness related business. The Group is also planning to set up overseas companies in markets with well-developed healthcare and wellness business such as Japan, Korea and Australia for introducing international products to China and vice versa.
4. The Group has adopted a strategy combining online and offline platforms. The Group has established the mobile based e-commerce department and established first-mover advantage in the “WeChat marketing” field by promoting products on WeChat, including micro-malls, public accounts, applications and other approaches. The Group has also obtained the licences required for e-commerce business and the value-added telecom service operation licences from the relevant administrators, and has set up online pharmacies as well as brand stores on Tmall.com and JD.com with increasing online sales. As to the offline platform, the Group owned 953 stores with over 1 million members and a national distribution network covering 6,500 distribution customers in 29 provinces as at 31 December 2014, which both recorded strong growth in sales. Embracing the trend of “internet + universal health”, the integrated online and offline platform will become the core competitive strength of the Group in the universal health field.

Based on the above, the Board believes that the Change of Company Name will better align with the Group’s strategy and development approach which will benefit the Company’s future business development, and is of the opinion that the Change of Company Name is in the interests of the Company and the shareholders of the Company (the “**Shareholders**”) as a whole.

CONDITIONS OF THE CHANGE OF COMPANY NAME

The Change of Company Name is subject to the following conditions:

1. the passing of a special resolution by the Shareholders approving the Change of Company Name at the forthcoming annual general meeting of the Company (the “AGM”); and
2. the Registrar of Companies in the Cayman Islands approving the Change of Company Name.

Subject to the satisfaction of the conditions set out above, the Change of Company Name will take effect from the date on which the certificate of incorporation on change of name is issued by the Registrar of Companies in the Cayman Islands. The Company will then carry out all the necessary registration and/or filing procedures with the Registrar of Companies in the Cayman Islands and the Companies Registry in Hong Kong.

In addition, subject to the confirmation of The Stock Exchange of Hong Kong Limited, the stock short name for trading in the shares of the Company will also be changed after the Change of Company Name becoming effective.

EFFECT OF THE CHANGE OF COMPANY NAME

The Change of Company Name will not affect any rights of the Shareholders. All existing share certificates in issue bearing the existing name of the Company will, after the Change of Company Name becoming effective, continue to be effective and as documents of title to the shares of the Company and valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for free exchange of the existing share certificates for new share certificates bearing the new name of the Company.

Should the Change of Company Name becoming effective, the shares in the Company will be traded under the new stock name and any issue of share certificates will be under the new name of the Company.

GENERAL

Special resolutions relating to the Change of Company Name will be put to vote at the forthcoming AGM for approval by the Shareholders.

A supplemental circular containing further details of the proposed Change of Company Name, together with a revised notice of AGM at which the resolutions relating to the proposed Change of Company Name will be put to vote, will be despatched to the Shareholders as soon as practicable. Further announcement(s) will be made by the Company in relation to the results of the AGM, the effective date of the Change of Company Name and the new stock short name for trading in the shares of the Company as and when appropriate.

By order of the Board
Jintian Pharmaceutical Group Limited
Jin Dongtao
Chairman

Hong Kong, 22 April 2015

As at the date of this announcement, the Board of the Company comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Chu Chuanfu and Mr. Yang Jiacheng and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Chen Xiao.